FTY720 also increased BCL-2 dependence in these treatment-naive primary CLL cells (Figure 12C), which subsequently increased sensitivity to venetoclax (Figure 12D). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.